Remove 2024 Remove Medicare Remove Technology
article thumbnail

HeartFlow AI Plaque Analysis Achieves Major Milestone Towards Medicare Coverage

DAIC

milla1cf Tue, 06/04/2024 - 20:54 June 4, 2024 — HeartFlow, a leader in cardiovascular healthcare technology, is pleased to announce a key Medicare policy development, which should allow for future expanded patient access to their Plaque Analysis product.

Medicare 104
article thumbnail

CMS Updates Medicare Coverage for AI-Coronary Plaque Analysis

DAIC

tim.hodson Wed, 10/16/2024 - 12:36 Oct. 15 , 2024 — Four of the seven Medicare Administrative Contractors (MACs) have released final local coverage determinations (LCD) for AI-Coronary Plaque Analysis (AI-CPA). The four contractors for the U.S. The LCDs have a future effective date of Nov.

CMS 52
article thumbnail

HeartFlow Introduces Next Generation Interactive Plaque Analysis Platform to Assess Patient Risk in Suspected Coronary Artery Disease

DAIC

mtaschetta-millane Thu, 07/18/2024 - 10:00 July 18, 2024 — HeartFlow, Inc. , The technology was introduced at the Society of Cardiovascular Computed Tomography (SCCT) Annual Scientific Meeting in Washington, D.C. JSCAI 2024. F.A.C.C. “The For more information: www.heartflow.com References: 1. Narula et al.

article thumbnail

CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

DAIC

tim.hodson Fri, 11/08/2024 - 09:57 Nov. 1, 2024 — Recor Medical, Inc. Centers for Medicare & Medicaid Services (CMS) have granted the company’s Paradise Ultrasound Renal Denervation system a Transitional Pass-through (TPT) payment. and its parent company, Otsuka Medical Devices Co. recently announced U.S.

CMS 40
article thumbnail

CDL Nuclear Technologies Launches New Mobile Cardiac PET/CT Trailer

DAIC

milla1cf Tue, 04/23/2024 - 16:03 April 23, 2024 — CDL Nuclear Technologies , a pioneer in advanced diagnostic solutions, is proud to announce the launch of its latest innovation: the Mobile dedicated Cardiac PET/CT Trailer. CDL provides this service in compliance with all healthcare regulations.

article thumbnail

Elixir Medical Granted FDA Breakthrough Device Designation for DynamX Bioadaptor

DAIC

The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease. 3 “We very much appreciate FDA’s breakthrough designation recognition of the bioadaptor technology,” continued Sirhan. Food and Drug Administration (FDA). of the U.S.

article thumbnail

Cardiac Wire’s Top 8 Takeaways from ACC 2024

CardiacWire

The ACC 2024 meeting is now complete, after over 17,000 cardiology professionals converged in Atlanta to witness cardiovascular medicine evolve in front of their eyes. The post Cardiac Wire’s Top 8 Takeaways from ACC 2024 appeared first on Cardiac Wire.